Teva and GlaxoSmithKline’s $400 Million Legal Dispute Over Patent Infringement Heads Toward Potential New Trial

The legal battle continues between Teva Pharmaceuticals and GlaxoSmithKline over allegations that Teva’s generic labeling induced healthcare providers to infringe on Glaxo’s patent for a heart drug. A Delaware federal judge has stated that several pivotal issues remain unresolved, particularly concerning the prospect of a new trial in this $400 million dispute. This ongoing litigation touches on significant legal questions surrounding patent infringement, specifically within the pharmaceutical industry. For further details on these developments, refer to the report on Law360.